XML 39 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration and Other Agreements - Zai Lab (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2018
Jun. 15, 2021
Dec. 31, 2020
Collaboration And Other Agreements [Line Items]                
Revenues $ 30,757 $ 20,257   $ 47,638 $ 33,939      
Common stock, par value (in dollars per share) $ 0.01     $ 0.01       $ 0.01
Deferred revenue, current $ 16,565     $ 16,565       $ 4,456
Deferred revenue, net of current portion 13,476     13,476       6,926
2018 Zai Lab Agreement | Zai Labs                
Collaboration And Other Agreements [Line Items]                
Non-refundable upfront payment           $ 25,000    
Non-refundable upfront payment, net of tax withholding           22,500    
Nonrefundable payment tax withholding           $ 2,500    
Potential development and regulatory milestone payments under agreement     $ 140,000          
Revenues     4,000          
Revenues, net of tax withholding     3,600   3,600      
Revenues, tax withholding     $ 400          
Deferred revenue 0     0       $ 0
Zai Lab Clinical Supply Agreements | Zai Labs                
Collaboration And Other Agreements [Line Items]                
Revenues 500 $ 300   1,600 $ 1,300      
Zai Lab Agreement, Margetuximab | Zai Labs | Maximum                
Collaboration And Other Agreements [Line Items]                
Potential proceeds from royalties (percent)           20.00%    
Zai Lab Agreement, TRIDENT molecule | Zai Labs                
Collaboration And Other Agreements [Line Items]                
Potential proceeds from royalties (percent)           10.00%    
2021 Zai Lab Agreements | Zai Labs                
Collaboration And Other Agreements [Line Items]                
Non-refundable upfront payment       25,000        
Potential development and regulatory milestone payments under agreement             $ 800,000  
Revenues 14,400     14,400        
Deferred revenue 21,000     21,000        
Opt-in fee             $ 85,000  
Proceeds of stock sale       30,000        
Sales of stock purchase price (in dollars per share)             $ 31.30  
Potential commercial milestone payments under agreement             $ 600,000  
Collaborative agreement transaction price             $ 40,400  
Variable consideration recognized       5,000        
Deferred revenue, current 13,200     13,200        
Deferred revenue, net of current portion $ 7,800     7,800        
2021 Zai Lab Agreements | Zai Labs | Additional Paid-In Capital                
Collaboration And Other Agreements [Line Items]                
Premium received on stock purchase       $ 10,400